Hyamedix - Pioneering Hyaluronic Acid Innovations
About us
Hyamedix is a leading developer and provider of cutting-edge solutions harnessing the power of hyaluronic acid, for aesthetic medicine, osteoarthritis treatment, and advanced drug delivery.
đ Our expertise: Unleashing the Potential of Hyaluronic acid
At the heart of our innovations lies our proprietary Hyaluronic Acid Cross-Linking Technology âHyalinkTM, setting new benchmarks in injectability, residence time, and rheological properties. This pioneering approach not only ensures unparalleled performance but also opens doors to revolutionary solutions in aesthetic procedures, osteoarthritis management, and precision drug delivery
Our Technology
Hyalink⢠X is our patented Hyaluronan (HA) cross linking technology.
đĄ Key advantages:
- Injectability: Our technology provides exceptional control over injectability, offering practitioners precision and ease in administering dermal fillers or visco-supplementation products.
- Residence Time: Experience extended therapeutic effects with our formulations, optimizing treatment outcomes and patient satisfaction.
- Rheological Properties: Tailored rheological characteristics enhance the versatility of our hyaluronic acid-based solutions, adapting to diverse medical applications with superior efficacy.
âď¸ Applications:
- Aesthetic Medicine: Elevate aesthetic procedures with our advanced hyaluronic acid formulations, ensuring natural-looking results and patient comfort.
- Osteoarthritis Treatment: Revolutionize osteoarthritis care with targeted and sustained relief, improving joint function and enhancing the quality of life for patients.
- Drug Delivery: Our technology opens avenues for precise and controlled drug delivery, optimizing therapeutic outcomes across various medical domains.
Partnership Approach
We believe in the power of collaboration. Hyamedix is not just a technology provider but a strategic partner committed to supporting our collaborators in their journey to success. Our partnership approach includes:
Product Development
Collaborate with us to bring your vision to life. Benefit from our expertise in product development, ensuring innovative and market-ready hyaluronic acid-based solutions.
Tech Transfer
Seamlessly integrate our technology into your processes through our comprehensive tech transfer services, facilitating a smooth transition from development to implementation.
Access to IP
Unlock the full potential of your projects with access to our intellectual property and know how.
Out-Licensing and Co-development
Explore new horizons by leveraging our out-licensing and co-development opportunities. Together, we can create impactful solutions that shape the future of healthcare.
Executive Management
MICHAEL FOLDAGER
Founder, Chief Executive Officer and Chairman of the Board of Directors
Mr. Foldager is a co-founder of Hyamedix, ApS and serves as the Chief Executive Officer. He also serves on the Board of Directors. Mr. Foldager brings over 15 yearsâ experience in the biotechnology sector and specifically within Hyaluronic Acid production, modification and product development.
KHADIJA SCHWACH-ABDELLAOUI
Chief BD & Strategy Officer and Member of the Board of Directors
Dr. Schwach-Abdellaoui is a seasoned healthcare executive with more than 30 years of extensive leadership and business experience in Pharma, medical devices and consumer health. She was previously Global head of BD and M&A Life science at VecturaFertin Pharma and prior to that she was business manager at DSM Pharma and diagnostics. Khadija is pharmacist and holds a PhD in oncology drug delivery and an executive MBA from Copenhagen business School. She has a strong HA scientific background and holds several patents and articles within the HA field.
BIRGIT FUHLENDORFF
Chief Development Officer
Ms. Fuhlendorff has served as Head of Formulation Development and Head of Hyamedix Labs since 2018. She has over 20 yearsâ experience in the biotechnology sector and specifically within Hyaluronic Acid production, modification and product development.Â
News
Press Release
1st April 2021
Hyamedix ApS Receives Funding to Accelerate Growth of Key Pipeline Projects.
Hyaluronan Conference 2021
14th - 15th of June, 2021
Virtual
Hyamedix will be attending virtually the Hyaluronan Conference 2021.
7th International Polysaccharide Conference
11th - 15th of October, 2021
Nantes, France
Hyamedix will be attending the 7th International Polysaccharide Conference.
Media & Publications
BY JEFFREY KROIN ET AL Published 24.06.16
Intraarticular steroid injection has been the mainstay of short-term treatment of knee osteoarthritis (OA) pain. However, the duration of therapeutic effect from a single injection is not as long as desired. In this study we use a viscous formulation of triamcinolone acetate (TCA) in hyaluronic acid to prolong the anti-allodynia effect of that steroid.
BY KEVIN GRĂNNEMANN Published 06.08.19 at 07:37
A group of former Novozymes employees have founded their own biotech company, Hyamedix, to continue development of a medical technology based on hyaluronic acid. Novozymes scrapped the technology in 2015 but the new company has high aspirations.
BY METTE LOUISE OHANA 2019.08.08
A technique for printing soft parts using a 3D printer which can, among other things, replace transplanted tissue, has just been outsourced to the company Hyamedix. Assistant Professor Dang Quang Svend Le from Aarhus University and Aarhus University Hospital is the man behind the invention.
